Effects of Levetiracetam on Episodic Ataxia Type 2 and Spinocerebellar Ataxia Type 6 with Episodic Ataxic Symptoms: A Case Series – PubMed Black Hawk Supplements

BLACK HAWK: Best ashwagandha supplement for adrenal fatigue

Published article

CONCLUSIONS: In this small number of cases, levetiracetam was considered effective in two patients with EA2 and mildly effective in one patient with SCA6.
Black Hawk Supplements, best supplements in the UK

Effects of Levetiracetam on Episodic Ataxia Type 2 and Spinocerebellar Ataxia Type 6 with Episodic Ataxic Symptoms: A Case Series - PubMed

Case Reports

Effects of Levetiracetam on Episodic Ataxia Type 2 and Spinocerebellar Ataxia Type 6 with Episodic Ataxic Symptoms: A Case Series

Haruo Shimazaki. Genes (Basel). .

Abstract

Background: Episodic ataxia type 2 (EA2) is a rare disorder characterized by paroxysmal gait instability, dysarthria, and dizziness. It is caused by CACNA1A mutations. Spinocerebellar ataxia type 6 (SCA6) rarely causes episodic ataxia-like symptoms. Acetazolamide has limited effectiveness for treating episodic ataxia.

Methods: We investigated the effect of drug therapy in two patients with EA2 and one patient with SCA6 who presented with episodic ataxia. All three cases were CACNA1A-associated diseases.

Results: In these three cases, acetazolamide administration was partially and transiently effective for episodic ataxia attacks. After levetiracetam addition, the number of ataxic attacks was significantly reduced, although the durations of attacks were not changed. The effect of levetiracetam was stable and continued for seven years. Levetiracetam and acetazolamide reduced chronic cerebellar ataxia in an SCA6 patient.

Conclusions: In this small number of cases, levetiracetam was considered effective in two patients with EA2 and mildly effective in one patient with SCA6.

Keywords: CACNA1A gene; acetazolamide; episodic ataxia type 2; levetiracetam; spinocerebellar ataxia type 6.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest.

Figures

Figure 1
Figure 1

Family trees of the episodic ataxia patients: (a) Case 1 (II-1), (b) Case 2 (III-1), (c) Case 3 (III-1). Cases 1 and 3 had no obvious family history. The family of Case 2 included patients with ataxia (II-4) and absence seizure (III-2) with the same CACNA1A variant (p.W1835*).

Figure 2
Figure 2

Brain MRI findings of the three patients. (a) Case 1, (b) Case 2, (c) Case 3. T1-weighted axial and sagittal images show mild upper cerebellar vermian atrophy.

Figure 3
Figure 3

Sequence analyses of CACNA1A in Cases 1 and 2. (a). A heterozygous 2 bp deletion variant (NM_001127222.2: c.2039-40 del AG (blue box), p.Q680R fs*16) was identified in Case 1. (b). A heterozygous nonsense variant (NM_001127222.2: c.5505G>A (red arrow), p.W1835*) was detected in Case 2. This variant was also detected in his mother (Figure 1b II-4) and sister (Figure 1b III-2).

Figure 4
Figure 4

Number of episodic ataxia attacks before and after levetiracetam administration. The number of episodic ataxia attacks was significantly reduced after levetiracetam administration in Case 1 (a) and Case 2 (b), and slightly reduced in Case 3 (c). (Unpaired t-test: **** p < 0.0001, ** p < 0.01.)

Similar articles

  • Episodic Ataxia Type 2 – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.

    Spacey S. Spacey S. 2003 Feb 24 [updated 2015 Oct 15]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2003 Feb 24 [updated 2015 Oct 15]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301674 Free Books & Documents. Review.

  • Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy.

    Rajakulendran S, Graves TD, Labrum RW, Kotzadimitriou D, Eunson L, Davis MB, Davies R, Wood NW, Kullmann DM, Hanna MG, Schorge S. Rajakulendran S, et al. J Physiol. 2010 Jun 1;588(Pt 11):1905-13. doi: 10.1113/jphysiol.2009.186437. Epub 2010 Feb 15. J Physiol. 2010. PMID: 20156848 Free PMC article.

  • GAA-FGF14-Related Ataxia.

    Pellerin D, Danzi M, Renaud M, Houlden H, Synofzik M, Zuchner S, Brais B. Pellerin D, et al. 2024 Jan 25. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2024 Jan 25. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 38271551 Free Books & Documents. Review.

  • Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.

    Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton CO, Hughes DA, Williamson PR, Baker G, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE. Marson AG, et al. Health Technol Assess. 2021 Dec;25(75):1-134. doi: 10.3310/hta25750. Health Technol Assess. 2021. PMID: 34931602 Clinical Trial.

  • Spinocerebellar Ataxia Type 6.

    Casey HL, Gomez CM. Casey HL, et al. 1998 Oct 23 [updated 2019 Nov 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 1998 Oct 23 [updated 2019 Nov 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301319 Free Books & Documents. Review.

References

    1. Olszewska D.A., Shetty A., Rajalingam R., Rodriguez-Antiguedad J., Hamed M., Huang J., Breza M., Rasheed A., Bahr N., Madoev H., et al. Genotype-phenotype relations for episodic ataxia genes: MDSGene systematic review. Eur. J. Neurol. 2023;30:3377–3393. doi: 10.1111/ene.15969. – DOI – PubMed
    1. Ophoff R.A., Terwindt G.M., Vergouwe M.N., van Eijk R., Oefner P.J., Hoffman S.M., Lamerdin J.E., Mohrenweiser H.W., Bulman D.E., Ferrari M., et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87:543–552. doi: 10.1016/S0092-8674(00)81373-2. – DOI – PubMed
    1. Zhuchenko O., Bailey J., Bonnen P., Ashizawa T., Stockton D.W., Amos C., Dobyns W.B., Subramony S.H., Zoghbi H.Y., Lee C.C. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat. Genet. 1997;15:62–69. doi: 10.1038/ng0197-62. – DOI – PubMed
    1. Jodice C., Mantuano E., Veneziano L., Trettel F., Sabbadini G., Calandriello L., Francia A., Spadaro M., Pierelli F., Salvi F., et al. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum. Mol. Genet. 1997;6:1973–1978. doi: 10.1093/hmg/6.11.1973. – DOI – PubMed
    1. Griggs R.C., Moxley R.T., 3rd, Lafrance R.A., McQuillen J. Hereditary paroxysmal ataxia: Response to acetazolamide. Neurology. 1978;28:1259–1264. doi: 10.1212/WNL.28.12.1259. – DOI – PubMed

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding

BLACK HAWK: Best lions mane supplement for men

Read the original publication:

Effects of Levetiracetam on Episodic Ataxia Type 2 and Spinocerebellar Ataxia Type 6 with Episodic Ataxic Symptoms: A Case Series – PubMed